Tirzepatide 15mg is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist being developed for type 2 diabetes treatment and weight management. Our pharmaceutical grade tirzepatide 15mg offers superior efficacy in glucose control compared to selective GLP-1 receptor agonists.
The compound demonstrates significant weight loss potential in clinical studies. In SURMOUNT-1 trials, the 15mg dose showed average weight reduction of 20.9% after 72 weeks. The molecular structure features PEG modification on the lysine side chain, enhancing water solubility while maintaining biological activity.
As a research chemical, tirzepatide 15mg represents an innovative approach combining the effects of two incretin hormones into a single molecule. The white powder formulation ensures stability and precise dosing for laboratory applications.
Our production facility maintains strict quality control measures throughout synthesis and purification processes. Each batch undergoes comprehensive analytical testing to verify identity, purity, and potency specifications.
The tirzepatide 15mg peptide is supplied in sealed vials with desiccant to maintain stability. Proper storage conditions include protection from light and moisture at controlled temperatures. For research use only - not intended for human consumption.